Hypertension and Heart Failure Prevention, Targets, and Treatment

被引：137

作者：

Di Palo, Katherine E. ^{[1
]}

Barone, Nicholas J. ^{[1
]}

机构：

[1] Montefiore Med Ctr, Off Med Director, 111 East 210th St, Bronx, NY 10467 USA

来源：

HEART FAILURE CLINICS | 2020年 / 16卷 / 01期

关键词：

Hypertension; Heart failure; Risk reduction; Pharmacotherapy; LEFT-VENTRICULAR HYPERTROPHY; BLOOD-PRESSURE REDUCTION; SCIENTIFIC STATEMENT; MANAGEMENT; OUTCOMES; RISK; INHIBITION; TRANSITION; CARDIOLOGY; MORTALITY;

D O I：

10.1016/j.hfc.2019.09.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hypertension is possibly the most powerful, modifiable risk factor for the development of heart failure. Chronic hypertension drives cardiac remodeling within the left ventricle resulting in hypertensive heart disease, which ultimately manifests as heart failure. Early detection and appropriate management are necessary to prevent heart failure as well as other cardiovascular diseases. Achieving blood pressure goals in conjunction with using evidence-based treatments can improve clinical outcomes for patients with comorbid hypertension and heart failure.

引用

页码：99 / +

页数：9

共 48 条

[1] Blood Pressure J-Curve: Current Concepts [J].

Banach, Maciej ;

Aronow, Wilbert S. .

CURRENT HYPERTENSION REPORTS, 2012, 14 (06) :556-566

[2] Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials [J].

Bavishi, Chirag ;

Messerli, Franz H. ;

Kadosh, Bernard ;

Ruilope, Luis M. ;

Kario, Kazuomi .

EUROPEAN HEART JOURNAL, 2015, 36 (30) :1967-1973

[3]

Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000746, 10.1161/CIR.0000000000000659]

[4] Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma [J].

Bhuiyan T. ;

Maurer M.S. .

Current Cardiovascular Risk Reports, 2011, 5 (5) :440-449

[5] Diastolic and Systolic Heart Failure Are Distinct Phenotypes Within the Heart Failure Spectrum [J].

Borlaug, Barry A. ;

Redfield, Margaret M. .

CIRCULATION, 2011, 123 (18) :2006-2013

[6] Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association [J].

Bozkurt, Biykem ;

Aguilar, David ;

Deswal, Anita ;

Dunbar, Sandra B. ;

Francis, Gary S. ;

Horwich, Tamara ;

Jessup, Mariell ;

Kosiborod, Mikhail ;

Pritchett, Allison M. ;

Ramasubbu, Kumudha ;

Rosendorff, Clive ;

Yancy, Clyde .

CIRCULATION, 2016, 134 (23) :E535-E578

[7] Epidemiology and risk profile of heart failure [J].

Bui, Anh L. ;

Horwich, Tamara B. ;

Fonarow, Gregg C. .

NATURE REVIEWS CARDIOLOGY, 2011, 8 (01) :30-41

[8] Cardiovascular Health in African Americans A Scientific Statement From the American Heart Association [J].

Carnethon, Mercedes R. ;

Pu, Jia ;

Howard, George ;

Albert, Michelle A. ;

Anderson, Cheryl A. M. ;

Bertoni, Alain G. ;

Mujahid, Mahasin S. ;

Palaniappan, Latha ;

Taylor, Herman A., Jr. ;

Willis, Monte ;

Yancy, Clyde W. .

CIRCULATION, 2017, 136 (21) :E393-E423

[9] Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) [J].

Cohn, JN ;

Pfeffer, MA ;

Rouleau, J ;

Sharpe, N ;

Swedberg, K ;

Straub, M ;

Wiltse, C ;

Wright, TJ .

EUROPEAN JOURNAL OF HEART FAILURE, 2003, 5 (05) :659-667

[10] Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction - The Reversal of ventricular remodeling with Toprol-XL (REVERT) trial [J].

Colucci, Wilson S. ;

Kolias, Theodore J. ;

Adams, Kirkwood F. ;

Armstrong, William F. ;

Ghali, Jalal K. ;

Gottlieb, Stephen S. ;

Greenberg, Barry ;

Klibaner, Michael I. ;

Kukin, Marrick L. ;

Sugg, Jennifer E. .

CIRCULATION, 2007, 116 (01) :49-56

← 1 2 3 4 5 →